Skip to main content
Ipsen Home Page
Press shift tab to select search category
Loading...
  • Newsroom arrow down
      < Back
    • Newsroom
    • Press Releases
    • Media Updates
    • emc易倍官网入口Media Resources
    • Media Contacts
    • Subscribe
  • Investors arrow down
      < Back
    • Investors
    • Investors
    • emc易倍官网入口Financial Results
    • emc易倍官网入口Annual Reports & Regulated Information
    • Investor Events & Financial Calendar
    • Shareholder Information
    • Subscribe
    • Ratings & Bonds
  • Careers arrow down
      < Back
    • Careers
    • Careers
    • Working at Ipsen
    • Culture
    • Job Search
  • Contacts arrow down
      < Back
    • Contacts
    • emc易倍官网入口Contacts
    • emc易倍官网入口Our Locations
    • Report Side Effects
    • Subscribe
  • Press shift tab to select search category
    Loading...
  • emc易倍官网入口 English  EN     Fran?ais  FR     EN  arrow_down
    • English EN
    • Fran?ais FR
  •  Global
    <
    • Global EN FR
    • Annual Report EN FR
    • Americas
    • Asia Pacific
    • Europe
    • Middle East & Africa
    • emc易倍官网入口 Brazil
    • Canada
    • United States
    • Mexico
    • emc易倍官网入口 Colombia
    • Australia
    • China
    • Singapore
    • South Korea
    • Japan
    • Belgium
    • Ukraine
    • UK
    • Germany
    • emc易倍官网入口 France
    • Nordics
    • Greece
    • Italy
    • Netherlands
    • Spain
    • emc易倍官网入口 Poland
    • emc易倍官网入口 Russia
    • Czech Republic
    • emc易倍官网入口 Romania
    • emc易倍官网入口 Hungary
    • Slovakia
    • emc易倍官网入口 Switzerland
    • Austria
    • emc易倍官网入口 UAE & Gulf
    • Saudi Arabia
  • Home
  • Company
      < Back
    • Company
    • Company
    • Leadership
    • History
    • Fondation Ipsen
  • Expertise
      < Back
    • Expertise
    • Oncology
    • Rare Disease
    • emc易倍官网入口Neuroscience
    • Medicines
  • Science
      < Back
    • Science
    • Science
        < Back
      • Science
      • Oncology
      • Rare Disease
      • Neuroscience
    • emc易倍官网入口Profiles
    • Partnering
        < Back
      • Partnering
      • Therapeutic focus
      • Meet the team
    • Clinical Trials
        < Back
      • emc易倍官网入口Clinical Trials
      • Lay Summaries
      • Find Clinical Trials
    • Pipeline
  • Sustainability
      < Back
    • Sustainability
    • emc易倍官网入口Sustainability
    • Environment
    • Patients
    • emc易倍官网入口People
    • emc易倍官网入口Governance
    • emc易倍官网入口Our Standards
  • Patients
      < Back
    • Patients
    • Patients
    • Together for Oncology
    • Together for Rare Disease
    • emc易倍官网入口Together for Neuroscience
    • Collaborate with us
  • Stories
  1. Home
  2. Newsroom – Newsroom – Subscribe to Ipsen News

emc易倍官网入口

IPN price

€163.10

 €-6.10 (-3.61%)

  • Media Resources
  • Annual Report
  • Contacts
  • Our Locations
Ipsen logo
LinkedIn Instagram Facebook Youtube
  • Terms and Conditions
  • Cookie Policy
  • Global Privacy Policy

? Ipsen Pharma. All rights reserved - 2026

You are now leaving the Ipsen group global website. To continue, please click on Continue?

Continue
We value your feedback

How easy was it to navigate Ipsen website and locate the information you were seeking?







2026-08-29 0:22:54